Investigation of Prevalence of Insulin Resistance and Metabolic Syndrome in Patients with Gastric and Colon Carcinoma
Mehmet Çelik1, Erdal Akyer1, Elif Yorulmaz1, Hilmi Çiftçi1, Veli Çakıcı1, Osman Köstek11Department of Internal Medicine, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
Objectives: The aim of this study was to determine the relationship between insulin resistance, metabolic syndrome (MetS) and the development of gastrointestinal system tumors. Methods: This study included 29 gastric cancer patients and 29 colorectal cancer patients who had been histopathologically diagnosed, and 30 healthy individuals. The patients and the control participants were evaluated for the presence of MetS using the International Diabetes Federation criteria. Insulin resistance was calculated using the Homeostasis Model Assessment of insulin resistance. The tomography results of subjects who were diagnosed with cancer were recorded according to presence of liver metastasis. Results: Overall, 27 (30%) of the patients were found to have MetS. MetS was confirmed for 31% of the gastric cancer group and 62.1% of the colon cancer group. The insulin resistance of colon cancer patients was significantly greater than that of gastric cancer patients (p<0.05). Conclusion: The frequency of MetS and insulin resistance in colon cancer patients was greater than that of the healthy population.
Cite This Article
Çelik M, Akyer E, Yorulmaz E, Çiftçi H, Çakıcı V, Köstek O. Investigation of Prevalence of Insulin Resistance and Metabolic Syndrome in Patients with Gastric and Colon Carcinoma. EJMI. 2018; 2(3): 168-171
Corresponding Author: Mehmet Çelik